An update of pitfalls in prostate mpMRI: a practical approach through the lens of PI-RADS v. 2 guidelines by Panebianco, V et al.
PICTORIAL REVIEW
An update of pitfalls in prostate mpMRI: a practical approach
through the lens of PI-RADS v. 2 guidelines
Valeria Panebianco1 & Francesco Giganti2 & Yu Xuan Kitzing3 & François Cornud4 &
Riccardo Campa1 & Gianluca De Rubeis1 & Antonio Ciardi1 & Carlo Catalano1 &
Geert Villeirs5
Received: 2 August 2017 /Revised: 21 September 2017 /Accepted: 26 September 2017 /Published online: 23 October 2017
# The Author(s) 2017. This article is an open access publication
Abstract
Objectives The aim of the current report is to provide an up-
date in the imaging interpretation of prostate cancer on
multiparametric magnetic resonance imaging (mpMRI), with
a special focus on how to discriminate pathological tissue
from the most common pitfalls that may be encountered dur-
ing daily clinical practice using the Prostate Imaging
Reporting and Data System (PI-RADS) version 2 guidelines.
Methods All the cases that are shown in this pictorial review
comply with the European Society of Urogenital Radiology
(ESUR) guidelines for technical mpMRI requirements.
Results Despite the standardised manner to report mpMRI
(PI-RADS v. 2), some para-physiologic appearances of the
prostate can mimic cancer. As such, it is crucial to be aware
of these pitfalls, in order to avoid the under/overestimation of
prostate cancer.
Conclusions A detailed knowledge of normal and abnormal
findings in mpMRI of the prostate is pivotal for an accurate
management of the wide spectrum of clinical scenarios that
radiologists may encounter during their daily practice.
Teaching Points
• Some para-physiologic appearances of the prostate may
mimic cancer.
• Knowledge of normal and abnormal findings in prostate
mpMRI is pivotal.
• Any radiologist involved in prostate mpMRI reporting
should be aware of pitfalls.
Keywords Prostate . Prostatic cancer . Magnetic resonance
imaging . Diagnosis . Pitfalls
Introduction
High-quality multi-parametric Magnetic Resonance Imaging
(mpMRI) has become an important tool in the diagnosis, char-
acterisation and treatment planning of prostate cancer (PCa)
[1–3]. Specifically, mpMRI involves T2-weighted anatomical
images combined with functional imaging methods such as
dynamic Contrast Enhanced Imaging (DCE), Diffusion-
Weighted Imaging (DWI) and/or Spectroscopy, if necessary.
All these sequences have a limited accuracy, when considered
individually, but their association has shown a greater perfor-
mance in the assessment of PCa [4].
However, inter-reader variability represents a real limitation for
prostate mpMRI, and expertise in reporting is crucial to improve
cancer detection and staging accuracy. Therefore, it is important to
validate the current protocols [5]. In 2012, the European Society
of Urogenital Radiology (ESUR) set up an expert panel to devel-
op a standardised system for prostate mpMRI interpretation and
reporting, under the name of Prostate Imaging Reporting and
Data System (PI-RADS) [6]. In 2015 a revision of this classifica-
tion led to the publication of PI-RADS v. 2 [7], with the aim to
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promote a global standardisation of these guidelines, and to re-
duce the variability in the acquisition, interpretation and reporting
of prostate mpMRI. A detailed explanation of PI-RADS v. 2 is
beyond the aim of this report, but it is worth summarising the
main points of these guidelines: (1) DWI is the dominant se-
quence in the peripheral zone (PZ); (2) T2-weighted imaging
(T2-WI) is the dominant sequence in the transitional zone
(TZ); (3) the role of DCE is secondary to DWI in the PZ;
and (4) there is an overall 5-point (from 1 to 5) PI-RADS
assessment (1: low probability – 5: very high probability of
clinically significant cancer).
Nonetheless, the interpretation of mpMRI of the prostate
can be challenging and new radiological skills are needed,
especially when potential pitfalls (i.e., normal anatomic struc-
tures, benign conditions of the prostate or artefacts due to
technical issues) might be erroneously interpreted as patho-
logical conditions. Moreover, the PI-RADS v. 2 guidelines
may be subject to some interpretation variability according
to the radiologists’ individual experience, lowering the ability
to distinguish pitfalls from true malignancy [8]. Awareness of
these pitfalls is therefore fundamental.
Currently, there are only three reports (two from the United
States and one from Europe) [9–11] addressing the mpMRI
pitfalls in PCa. They have all suggested some strategies to assist
the radiologists in avoiding misdiagnosis (and consequently
mistreatment), but a systematic approach on how to tackle these
aspects applying PI-RADS v. 2 has yet to be reported.
Therefore, the purpose of this article is to provide a practi-
cal approach for imaging interpretation in PCa, with a special
focus on how to apply PI-RADS v. 2 to discriminate
pathological conditions from the most common pitfalls that
could be encountered during daily clinical practice. Of note,
this report is based on a pragmatic consensus among a panel of
different international radiologists highly experienced in
mpMRI of the prostate (VP, FG, YXK, FC, GV).
PITFALLS and PI-RADS v.2
For the sake of completeness, the cases shown in this pictorial
report represent a cohort of men aged 47–79 years, with prior
suspicion of PCa based on abnormal digital rectal examina-
tion, rise of prostate specific antigen (PSA) and/or family his-
tory of PCa. The exams have been acquired on a 3.0 T system
(DiscoveryMR750, GE Healthcare, Waukesha, WI), by using
a 32 multi-channel (or 8 multi-channel + endorectal coil) sur-
face phased-array body coil.
Awareness of diagnostic pitfalls is important to avoid both
false-positive and false-negative interpretations. A systematic ap-
proach to mpMRI of the prostate using PI-RADS v. 2 helps in
the identification of PCa, but there still remains a wide spectrum
of pitfalls. These can be broadly split into two main groups: (1)
pitfalls related to clinical indications and (2) technical and phys-
iological artefacts (Table 1).
Pitfalls related to clinical indications
These pitfalls are related both to the anatomy of the prostate
and to certain benign conditions of the gland, which can
Table 1 Wide spectrum of
pitfalls and different
classifications
Pitfall Pitfall vs Pitfall
Anatomic
1. Hypertrophic anterior fibromuscular stroma
Benign conditions
1. Moustache sign (small bilateral BPH
nodules against the PZ)
2.Moustache-like sign (larger adenoma against the PZ)
3. Teardrop sign (median posterior
compressed central zone)
4. Teardrop-like sign (Protruding BPH
above the verumontanum)








I. PCa in moustache sign
II. PCa in median posterior change
(compressed central zone and BPH proliferation)
in reversed teardrop
III. Ectopic BPH nodule vs abscess
BPH = benign prostatic hyperplasia; PZ = peripheral zone; PCa = prostate cancer
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mimic the presence of cancer. The typical appearance of PCa
in the PZ is a focal hypointense area on T2-WI; however, other
benign conditions, such as prostatitis, fibro-muscular bands
and post-biopsy haemorrhage can mimic this signal change,
leading to potential misdiagnoses.
Anatomic pattern
Hypertrophic anterior fibromuscular stroma
This is related to the presence of muscle cells and connective
tissue in the most anterior part of the gland, between the two
lobes that constitute the TZ. This condition is characterised by
an area of homogeneous, very low signal intensity on T2-WI,
usually with lenticular shape (scored as 4/5 or 5/5 according to
PI-RADS v. 2). However, hypertrophic anterior fibromuscular
stroma does not commonly show enhancement on DCE nor
significant restriction on DWI (score 1 or 2), even though low
ADC values can be seen sometimes, due to pre-existing low
T2-signal areas rather than a true restriction. Therefore, our
suggestion is to use all the available planes, including the
coronal and sagittal planes. An additional acquisition plan is
of utmost importance, as it can confirm the continuity of the
hypertrophic anterior fibromuscular stroma with the benign
tissue. Such an approach, together with negative DWI and
DCE findings, can help to rule out the presence of clinically
significant PCa (Fig. 1).
Periprostatic neurovascular bundle
The periprostatic vascular (sometimes venous) plexus courses
around the lateral margins of the prostate (i.e., very close to the
capsule) and can show a congested appearance, particularly in
men with prostatitis.
Sometimes it is difficult to separate the plexus from the PZ
on mpMRI, due to focal low T2 signal intensity. This makes
the use of PI-RADS v.2 mandatory.
According to PI-RADS v. 2, the plexus can be scored as 3–
4/5 on T2-WI, due to its mass-like appearance. Sometimes,
this anatomical structure can show a mildly restricted diffu-
sion (3/5) – only on Echo-planar sequence and not on the
ADCmap, due to the slow speed of blood flow - together with
focal enhancement (+), and in continuity with the vessels,
raising the suspicion of clinically significant PCa (mimicking
T3a stage disease). In order to rule out the presence of a tu-
mour, it is of paramount importance to take into account the
appearance of the periprostatic plexus on T2-WI, as well as on
delayed subtracted contrast-enhanced images (Fig. 2).
The neurovascular bundle courses along the posterolateral
margin of the prostate, near the prostate capsule, at approxi-
mately a 5- and 7-o’clock position.
Similar to the periprostatic vascular plexus, the
neurovascular bundle, when visible, can mimic the presence
of a lesion in the PZ (mimicking T3a disease).
When difficult to discriminate from PZ, the neurovascular
bundle can be scored as 4/5 on T2-WI according to PI-RADS
v. 2, due to the very low signal intensity on this sequence.
However, the neurovascular bundle can show restriction on
DWI (4–5/5) due to signal from myelinated fibres and is
characterised by a mild, enhancement pattern (+), tangent to
the capsule. In this case the application of PI-RADS v. 2, and
the knowledge of anatomy on DWI and DCE sequences is
decisive to rule out the presence of PCa (Fig. 3).
In case of a tumour located adjacent to the periprostatic
neurovascular bundle, the distinction might not be easy due
to the absence of the adipose plane between them. At this
regard, DCE sequences can be of help due to the different
behaviour after contrast injection (early vs late/mild enhance-
ment). Additionally, the coronal plane can help to localise the
neurovascular bundle and the continuity of the capsule in an-
other plan.
Moreover, mpMRI is increasingly being used in the
decision-making pathway of PCa, to support the choice of a
nerve-sparing approach when possible. In this regard, the use
of diffusion-tensor imaging from mpMRI holds promise for
the future [10].
Benign conditions
Bilateral benign prostatic hyperplasia proliferation
(moustache sign)
The presence of median symmetric, bilateral areas of low sig-
nal intensity on T2-WI at the base/middle of the prostate on
either side of the ejaculatory ducts can mimic cancer. This set
of appearances has been called the “moustache sign”, and can
be ascribed to two main conditions. The first is the compres-
sion of the central zone by small nodules of benign prostatic
hyperplasia (BPH) against the PZ, and this typically occurs in
the posterior portion of the prostate, at the base or mid-gland
level (moustache sign) (Fig. 4). The second finding is related
to the protrusion of a much larger adenoma in the PZ, and this
also occurs in the posterior portion of the prostate, at the base
(moustache-sign like) (Fig. 5).
On the contrary, foci of PCa generally show a more hetero-
geneous appearance, with ill-defined margins.
Histologically, the low signal intensity reflects respectively
the compressed central gland, with hypertrophic tissue, and
the different glandular pattern of BPH, with increased cellu-
larity. In both cases, this sign typically appears as a symmet-
rical oval shape, with sharp margins and a homogeneous, low
signal intensity.
These regions can also be characterised by restricted diffu-
sion and homogeneous/positive enhancement. Protrusion of
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BPH nodules shows homogeneous enhancement, whereas the
compressed central zone usually does not.
According to PI-RADS v. 2, a potential score for this pitfall
could be 3–4/5 for T2-WI, 4/5 for DWI (in case of marked
restriction of diffusion) and early enhancement (+) on DCE;
such scenario would orient towards the presence of clinically
significant PCa and might suggest biopsy. However, if we
apply PI-RADS v. 2 after carefully considering other
distinguishing features (e.g., the use of the coronal T2 weight-
ed sequence, the presence of sharp margins and a symmetrical
Fig. 2 Periprostatic bundle. The arrow in the axial T2-weighted image
(a) shows an area of intermediate to low-signal intensity in the right
peripheral zone. This corresponds to mild, restricted diffusion on the
echo-planar diffusion-weighted sequence (b), due to the slow speed of
blood flow and focal enhancement on DCE imaging (c)
Fig. 1 Hypertrophic anterior fibromuscular stroma vs cancer. Axial (a)
and coronal (b) T2-weighted images that show an area of homogeneous
low signal intensity with a lenticular shape (white arrows), and not
significant restriction in the ADC map (c). The red arrows show a small
focus of prostate cancer in the anterior right gland (a), corresponding to an
area of restricted diffusion in the ADC map (c). These findings were
confirmed at final histology, after radical prostatectomy (GS = Gleason
score 4 + 3) (d)
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pattern), we can correctly score this condition as 2/5 both on
T2-WI and DWI, excluding the presence of cancer (Figs. 4
and 5). It follows that an appropriate use of PI-RADS v. 2
guidelines is based on the knowledge and awareness of the
anatomy related to BPH nodules in the central zone.
We also want to stress that the key feature to differentiate a
pitfall from PCa is the symmetry of the finding. An asymmet-
rical area characterised by lower signal intensity on T2-WI
with respect to the background (3) together with a marked,
focal enhancement (+) and higher grade of restriction on DWI
(4) suggests a suspicious lesion in this context.
This is a clear example where the radiologist could be ini-
tially misled by PI-RADS v.2 but the knowledge of both the
anatomy and the pitfall assists in the detection of PCa (cancer
in moustache sign) (Fig. 6).
Median posterior BPH proliferation (teardrop sign)
The presence of a focal/nodular, hypointense area at the
middle third or at the base (adjacent to the ejaculatory ducts)
of the PZ of the prostate could mimic cancer. This aspect is
a variant/extension of the previously described moustache
sign, in which the central zone is compressed between the
TZ and PZ, adopting a teardrop shape (Fig. 7).
Here, the pitfall is related to a posterior bulging of the
central zone above the verumontanum, between the TZ
and the PZ (teardrop), and could show mild, restricted
diffusion and focal contrast uptake. The low signal inten-
sity of this finding on T2-WI is due to the hypertrophic
tissue that follows the ejaculatory ducts before entering
the prostatic urethra.
Fig. 3 Neurovascular bundle vs cancer. The white arrows show the
neurovascular bundle in the axial T2-weighted (a) and DW (b)
images, and in the DCE map (c). The high signal intensity on DWI
(i.e., restriction) on DWI is due to myelinated nerve fibres. The red
arrows show a tumour in the right anterior gland. These findings were
confirmed at final histology, after radical prostatectomy (GS =Gleason
score 3 + 4) (d)
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It follows that the verumontanum plays a crucial role to
distinguish between the compressed central zone and protrud-
ing BPH. If our finding lies above the verumontanum, this can
be due to both a bulging central zone (teardrop sign) or a
protruding BPH (teardrop-like sign), while only BPH will
be present below the verumontanum. Figure 8 is a summary
of these signs (moustache or teardrop) at different levels.
According to PI-RADS v. 2, a potential score for this pitfall
could be 3/5 for T2-WI, 3/5 for DWI and early enhancement
(+) on DCE, suggesting the presence of clinically significant
PCa, with an overall score of 4/5. We want to emphasise that
the use of the coronal and/or sagittal plane is very important to
demonstrate the continuity and symmetry of this area with the
rest of the central portion of the gland, and it is crucial to
differentiate a pitfall from PCa (cancer in pitfall) (Fig. 9). As
already discussed for themoustache sign, the radiologist could
Fig. 4 The arrows show two median, symmetric, bilateral areas of low
signal intensity on axial (a) and coronal (c) T2-weighted imaging, with
restricted diffusion in the ADCmap (b) and diffuse enhancement onDCE
imaging (e). This set of appearances has been called the “moustache sign”
Fig. 5 Axial T2-weighted image (a) of the posterior base. The yellow
areas (b) correspond to the protrusion of a large adenoma in the peripheral
zone (moustache-sign like), as confirmed at final histology, after radical
prostatectomy (c)
92 Insights Imaging (2018) 9:87–101
be initially misled by PI-RADS v.2 but the knowledge of both
the anatomy and the pitfall can assist in the detection of PCa in
the presence of a reversed teardrop area.
An area that is not in continuity with the central portion of
the prostate, characterised by marked low signal intensity on
T2-WI (scored as 4/5) together with an early uptake of con-
trast (+) and a high grade of restriction on DWI (scored as 4/5)
can be correctly classified as a highly-suspicious lesion.
Again, it is very important to understand the mpMRI anat-
omy of the prostate to detect cancer in the context of a pitfall
Fig. 6 The yellow area is the moustache sign. The arrows show a focal,
asymmetric area characterised by low signal intensity on coronal (a) and
axial (b) T2-weighted imaging, together with marked restriction on DWI
(c). These findings suggest a suspicious lesion in the left peripheral zone
(cancer inmoustache sign), and this was confirmed at final histology after
radical prostatectomy (GS = Gleason score 4 + 4) (d)
Fig. 7 Axial T2-weighted image (a) that shows a hypointense area at the
prostate base, in the peripheral zone. This aspect is a variant/extension of
the moustache sign, in which the central zone is compressed between the
transitional and peripheral zones, adopting a teardrop shape, as
represented by the yellow area in the coronal T2-weighted image (b)
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(median posterior BPH proliferation). Sometimes some fibrot-
ic tissue can be seen adjacent to the ejaculatory ducts. This is a
low-signal intensity area, with restricted diffusion but showing
late enhancement on DCE imaging (i.e., there is no early con-
trast uptake like in PCa) (Fig. 10).
Ectopic BPH nodule
The presence of an ectopic, focal peripheral nodule
characterised by low signal intensity on T2-WI, with sharply
defined margins, restricted diffusion and enhancement similar
to the central portion of the hypertrophied TZ, could be erro-
neously interpreted as PCa in the PZ [12–13]. Moreover, the
presence of the pseudocapsule along with tiny bright spots
(corresponding to dilated acini) is consistent with a nodule
of stromal BPH, which may sometimes protrude from the
central zone. Not recognising an ectopic nodule of BPH in
the PZ may lead to the use of DWI as dominant sequence in
the PZ, grading this area as 4/5. Conversely, in the presence of
an ectopic nodule, T2-WI can be used to score this zone, as
this is the dominant sequence for the TZ. Such an approach
would yield a 2/5 score and, therefore, downgrade the finding
from a malignant lesion to a benign condition (Fig. 11).
However, as there are no established guidelines that sug-
gest scoring a TZ lesion that protrudes into the PZ using the
dominant sequence from the TZ (rather than PZ), we deem
Fig. 8 Summary of the different signs (moustache or teardrop) at different levels. CZ = central zone; BPH: benign prostatic hyperplasia;
ED = ejaculatory ducts
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that in this scenario the experience of the radiologist and the
knowledge of prostate anatomy and specific morphological
features of BPH (e.g., regular capsule and margins) are more
important than ever.
Fig. 10 Axial T2-weighted image (a) that shows a focal area of low
signal intensity adjacent to the ejaculatory ducts (white arrow). This
corresponds to an area of restricted diffusion on the ADC map (b) and
late enhancement on DCE imaging (c) and represents fibrosis, as
confirmed at final histology after radical prostatectomy (d)
Fig. 9 The arrows show a focal area with low-signal intensity on axial (a) and coronal (c) T2-weighted imaging, and restricted diffusion on DWI (b) at
the prostate apex. The use of the coronal plane is very important to differentiate a pitfall (teardrop) from prostate cancer (cancer in pitfall)
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Prostatitis
This condition is usually caused by E. coli or Staphylococcus
infections, and can ultimately result in the formation of an
abscess.
On mpMRI, focal prostatitis can show an area of decreased
signal on T2-WI (from nodular to band-like) in the PZ (adja-
cent to the capsule and infiltrating the periprostatic fat; hence,
mimicking extracapsular extension – T3 stage) and increased
perfusion on DCE (+), yielding a “false positive” finding.
Additionally, the ADC map can be characterised by an area
of low signal intensity.
According to PI-RADS v.2, the aforementioned findings
can be scored at least 4/5, suggesting the presence of clin-
ically significant PCa. However, the clinical history plays a
crucial role in the diagnosis of focal prostatitis vs the pres-
ence of PCa (incidental finding), as this latter shows an
earlier and more avid enhancement (cancer in pitfall)
(Fig. 12).
Therefore, final histopathology is regarded as the only
means to carry out an accurate diagnosis and to exclude the
presence of tumour.
In addition, the radiologist should keep in mind that also
granulomatous prostatitis can occur in the prostate. This usu-
ally presents as a firm nodule on digital rectal examination and
elevated PSA, thus mimicking PCa. Although there can be
different causes (instillation of intravesical bacille of
Calmette-Guérin for bladder cancer, tuberculosis, surgical
procedures), most cases are usually idiopathic [9].
Abscess vs cancer
In the PZ, it is possible to find a round-shaped region
characterised by inhomogeneous, low-signal intensity on
T2-WI, with a pseudocapsule (scored as 2/5), together with
ring enhancement on DCE (+) and restriction on DWI (scored
as 4/5).
Fig. 11 The arrows show a focal nodule bulging in the left peripheral
zone, characterised by low signal intensity on axial (a) and coronal (c) T2-
weighted imaging, with sharply defined margins, and restricted diffusion
on the ADC map (b). The presence of tiny bright spots (corresponding to
dilated acini) is consistent with a nodule of stromal benign prostatic
hyperplasia (BPH), which may sometimes protrude from the central zone
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In this context, one might argue that PI-RADS v.2 is erro-
neously suggesting the presence of clinically significant PCa,
but the specific ring enhancement together with the clinical
history (e.g.. fever) can orient towards the correct diagnosis of
abscess (Fig. 13).
Haemorrhage and other pitfalls
The presence of haemorrhage after prostate biopsy is relatively
frequent. In fact, citrate is normally produced by the prostate for
preserving the semen, but it is also an endogenous anticoagu-
lant that can lead to protracted bleeding and non-coagulation of
blood after biopsy. The latter may cause decreased T2 signal
intensity that could mimic or obscure a suspicious area for PCa.
Using a strict approach of PI-RADS v.2 guidelines, this should
be grading as 4/5 on T2 and 4/5 on DWI, with a low ADC.
However, the pre-contrast T1-WI can help to differentiate this
area from a suspicious focus of PCa, as it shows a mild hyper-
intense signal due to the products from the haemoglobin
degradation. This will be also supported by the corresponding
hypointense signal in the post-contrast subtraction imaging.
When the clinical question is detecting PCa, it is of utmost
importance to impose a delay after biopsy, to allow time for re-
absorption of blood products (approximately 4–8 weeks)
(Fig. 14). The delay could be different based on why
mpMRI is done (i.e., detection vs staging). As staging is more
dependent on T2-WI, delay after biopsy for staging is more
desirable, while for detection it might not be necessary.
Focal atrophy - particularly the post-atrophic hyperplastic
subtype - may mimic PCa on mpMRI due to the glandular
crowding and complex architecture. Causes of atrophy in-
clude inflammation, irradiation, antiandrogen therapy, and
chronic ischaemia from local arteriosclerosis. Focal atrophy
occurs more frequently in the PZ and appears as a focal or
geographical area of low T2 signal intensity on mpMRI, with
both moderate diffusion restriction and enhancement. The de-
gree of restriction and tissue enhancement are usually less
marked than PCa.
Fig. 12 The red arrows show a focal area in the right peripheral zone
with low-signal intensity on axial T2-weighted imaging (a), restricted
diffusion in the ADC map (b), avid enhancement in the DCE study (c)
and an early wash-in curve (d); these findings are consistent with prostate
cancer (Gleason 3 + 3). Thewhite arrows show a diffuse area of decreased
signal in the left peripheral zone on T2-weighted imaging (a), and a mild
restriction in the ADCmap (b) and diffuse contrast uptake (c and d); these
findings are consistent with prostatitis
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Fig. 14 The arrows show an area of mild, low-signal intensity on T2-
weighted imaging (a), with restricted diffusion on DWI (b) and in the
ADC map (c). This corresponds to a hyperintense area on pre-contrast
T1-weighted imaging (d), which is consistent with the products from the
haemoglobin degradation after biopsy, as also supported by the post-
contrast subtraction imaging (e) and in the colour DCE map (f). DCE
studies have been obtained by gradient-echo sequences (TR: 4,5 ms; TE:
1,5 ms; flip angle: 15°; Average: 4; slice thickness: 2 mm; Matrix:
320 × 320; Scan Time: 3.13 min), using a body-weight adjusted
intravenous bolus of gadobutrol (Gadovist, 1 mmol/mL; Bayer
Schering Pharma, Berlin, Germany). DWI parameters were: TR ≥
3000 ms; TE ≤ 90 ms; slice thickness ≤ 4 mm, no gap; field of
view:160–220 mm; in plane dimension ≤ 2.5 mm phase and frequency;
b values for DWI were 0–500- and values ranging between 1000 and
3000 s/mm2. For ADC maps, if only two b values can be acquired, it is
preferred that the lowest b value should be set at 50–100 s/mm2 and the
highest should be 800–1000 s/mm2
Fig. 13 The first four images show a round-shaped area characterised by
intermediate signal intensity on T2-weighted imaging (a), restricted
diffusion on DWI (b) and in the ADC map (c), and ring enhancement
(d). These findings, together with clinical history, orient towards the
diagnosis of abscess. The other four images show a focal nodule in the
right anterior peripheral zone, characterised by low signal intensity on
axial T2-weighted imaging (e) with sharply defined margins and tiny
bright spots, and restricted diffusion on DWI (f) and in the ADC map
(g), and homogeneous enhancement on DCE imaging (h). These findings
are consistent with an ectopic nodule of BPH
98 Insights Imaging (2018) 9:87–101
Necrosis can be seen after the resolution of the abscess and
florid inflammatory changes from an infectious prostatitis, or
after focal therapy. Necrosis shows lowT2 signal intensity and
diffusion restriction, due to the coagulative state characterised
by reduced water movement, as well as by the adjacent in-
flammatory infiltrate and atrophy. There is also no enhance-
ment. Together, these features suggest the presence of necrosis
and fibrosis on mpMRI.
Calcification is due to concreted prostatic secretions, calci-
fied corpora amylacea and phleboliths in the periprostatic ve-
nous plexus. Calcifications show low signal intensity on T2-
WI and ADC images, together with no enhancement and a
persistent, marked low signal intensity on DWI at all b values.
All the aforementioned pitfalls (focal atrophy, necrosis and
calcifications) have specific features that help to distinguish
them from PCa when applying PI-RADS v. 2 (e.g., no en-
hancement or less restriction on DWI).
Pitfalls related to technical and physiological
artefacts
The use of an endorectal coil in addition to the surface coil
improves the signal-to-noise ratio and the spatial resolution
both at 1.5 and 3 T. On the contrary, patient or bowel move-
ments during image acquisition may cause repetitive circular
artefacts along the boundaries of the endorectal coil. These
artefacts can be minimised by rectal emptying and by the
administration of a spasmolytic drug prior to the examination.
According to PI-RADS v. 2, an area of homogeneous low-
signal intensity on T2-WI in the PZ, showing restricted diffu-
sion on DWI and focal enhancement (+) can be scored as 4/5,
suggesting the presence of clinically significant PCa. However,
the use of a single surface coil could erroneously suggest
extracapsular extension (T3 stage) because of the lower resolu-
tion. In this case, the application of PI-RADS v. 2 together with
the use of the endorectal coil could help to rule out capsular
involvement (T2 stage), thanks to the increased resolution.
The endorectal coil should be positioned correctly, in order
to avoid the risk of incurring potential diagnostic pitfalls that
could mimic the presence of PCa. The correct position of the
coil is in a plane perpendicular to the left-right phase encoding
direction. If the coil is not positioned properly, it is possible to
see a focal area of enhancement (+) with restricted diffusion
(scored 4/5 according to PI-RADS v. 2) adjacent to the coil
surface. This finding could be erroneously interpreted as a
lesion (Fig. 15), but the ADC maps and T2-WI do not show
this artefact, and therefore PCa can be ruled out.
Fig. 15 Thewhite arrows show an areamimicking restricted diffusion on
DWI (a) and focal enhancement onDCE imaging (b) in the left peripheral
zone, very close to the prostatic capsule and adjacent to the endorectal coil
surface. This finding could be erroneously interpreted as a lesion, but the
axial T2-weighted image (c) does not show this artefact, and therefore
prostate cancer can be ruled out. Red arrows show the coil surface
Insights Imaging (2018) 9:87–101 99
To sum up, there are different artefacts that can mimic the
presence of PCa and which the radiologist should be aware of.
These include the presence of gas in the rectum, and the inter-
pretation of ADC maps with low-value pixels, as these latter
can show the same dark signal as fat, creating problems for
lesions along the capsule. As far as the use of spasmolytic
agents is concerned, the radiologist should bear in mind that
many patients undergoing mpMRI will have a large prostate
due to BPH (with related urinary problems). Therefore, these
medications should be administered carefully and preferably
before positioning the patient on the mpMRI table. Glucagon
should be chosen in patients with urinary retention.
Conclusions
Since its introduction, mpMRI of the prostate has been
changing the management of suspicious PCa, especially
in men with non-specific high PSA, where the detection
of clinically significant PCa has been shown to be more
accurate than standard TRUS biopsy [14]. Despite the
standardised attempts to report mpMRI (PI-RADS v 2)
[7], some para-physiologic appearances of the prostate
gland can mimic cancer. As there are no established guide-
lines that suggest scoring a TZ lesion that protrudes into
the PZ using the dominant sequence from the TZ (rather
than PZ), we deem that in this scenario the experience of
the radiologist and the knowledge of prostate anatomy and
specific morphological features of BPH (e.g., regular cap-
sule and margins) are more important than ever. Moreover,
we believe that the radiologist should be aware of clinical
data such as the exposure to antiandrogen therapy for BPH,
as this could affect the conspicuity of tumours in the TZ as
well as on DWI. The radiologist should also keep in mind
that other sequences (e.g., DWI) can be of great help while
reporting prostate mpMRI, if there are some doubts on T2-
WI, as suggested by the PI-RADS v. 2 guidelines [15–21].
Although these guidelines use DWI to upgrade some PI-
RADS 3 lesions in the TZ to PI-RADS 4, DWI alone is
nonetheless a sensitive sign for detection of tumours even
in the TZ [22–23]. Rosenkrantz and colleagues [22] report-
ed that the incorporation of DWI and ADC maps (b
value:1000 s/mm2) significantly improves the sensitivity
for TZ tumours compared with T2-WI alone. The main
reason is the diffuse background heterogeneity and the
presence of multiple nodules in the TZ, which make tu-
mours harder to identify on T2-WI. As known, DWI inves-
tigates the movement of water molecules within tissues and
reflects changes in cellularity; thus, it provides comple-
mentary information that may help depict lesions not ini-
tially visible on T2-WI, leading to improved sensitivity.
In conclusion, we recommend that any radiologist in-
volved in prostate mpMRI be fully aware of the pitfalls
mentioned in this pictorial report, in order to avoid under-
estimation and overestimation of PCa detection. We also
deem that this manuscript gives a repertoire of potential
solutions for the improvement of the future PI-RADS
guidelines.
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